INTRODUCTION
Although cure rates for pediatric acute lymphoblastic leukemia (ALL) approach 90%, outcomes in high-risk subgroups and salvage rates remain poor. 1 As conventional chemotherapy is optimized currently to near-maximal tolerable intensity, novel approaches such as immunotherapy are vital to improve outcomes in high-risk disease.
It is well established that natural killer (NK) cells have a critical role in the innate immune response against malignancies, including leukemia. 2, 3 The ability of NK cells to kill targets or produce cytokines depends on the balance between signals from activating and inhibitory cell-surface receptors. Activating receptors, which include the natural cytotoxicity receptors NKp46, NKp30, NKp44 and NKG2D, [4] [5] [6] recognize stress molecules upregulated on transformed or virally infected targets; however, the cognate ligand for many activating receptors remains unknown. 7 Inhibitory receptors, notably the killer immunoglobulin-like receptors (KIRs) and the C-type lectin NKG2A, are specific for different human leukocyte antigen (HLA) molecules on target cells, and transmit signals that inhibit NK cytotoxicity upon engagement. 8 Accordingly, NK cells can kill targets that have downregulated surface HLA class-I molecules. Cancer cells can impair NK function through a number of mechanisms including modulation of their surface receptors, 9 and release of soluble factors with immunosuppressive properties such as interleukin-10 (IL-10) or tumor growth factor-β (TGF-β).
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Here, we show that mechanisms of tumor escape from NK cellmediated immunity occur in childhood B-ALL. In a cohort of childhood B-ALL patients sampled at diagnosis, end induction and maintenance therapy, we found evidence of altered NK phenotype and function compared with age-matched controls. The abnormalities only partially corrected during maintenance therapy and could be induced in healthy NK cells following coculture with ALL blasts in vitro via the release of soluble factors, notably TGF-β1. Finally, we report higher expression of phospho-SMAD2/3, the most important signal transducers for transmission of TGF-β1 intracellular signaling, 14 in ALL-NK cells at diagnosis and end induction compared with maintenance therapy or healthy controls, thus providing mechanistic insights into the critical role of TGF-β in inducing NK dysfunction in childhood ALL. Taken together, these data suggest that ALL blasts through the release of immunomodulatory factors, critically TGF-β1, induce long-lasting changes in NK cells to evade immune surveillance.
MATERIALS AND METHODS
Samples were collected following informed consent from 50 consecutive patients with newly diagnosed B-ALL at Texas Children's Cancer Center Phenotyping PBMCs were immunostained with CD56 and CD3 monoclonal antibodies to identify the NK population (CD56+CD3 − ), and with CD10/CD19 monoclonal antibodies (BD Biosciences, San Jose, CA, USA) to exclude ALL blasts. NK cells were analyzed for the expression of natural cytotoxicity receptors (NKp30, NKp44, NKp46), activating/inhibitory C-type lectins (NKG2D/NKG2A) and KIRs (KIR2DL1/S1, KIR2DL2/L3, KIR3DL1) (BioLegend, San Diego, CA, USA). Blasts were analyzed for the expression of relevant NK ligands: HLA-A/B/C (ligands for inhibitory KIRs), major histocompatibility complex class-I chain-related genes A/B (MICA/ B, ligands for NKG2D), HLA-E (ligand for NKG2A) and HLA-DR4/5 (BioLegend). Controls for blast phenotyping included negatively selected healthy B cells using the B-Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were acquired using an LSRII Cytometer (BD Biosciences) and analyzed using the FlowJo software version 7.6 (Tree Star, San Carlos, CA, USA).
Cytotoxicity studies
Twenty patients had PBMCs available from DX, IND-29 and maintenance therapy. Cells from each time point were thawed, stained and analyzed on the same day to minimize variability. PBMCs were rested in RPMI/FCS 10% (Roswell Park Memorial Institute/fetal calf serum 10%) overnight and incubated with targets for 5 h at an NK:target ratio of 1:1, based on sample NK frequency. Targets included major histocompatibility complex class-I-deficient K562 cells (grown in RPMI/FCS 10%) and autologous blasts. Negative and positive controls included PBMCs cultured alone or stimulated with phorbol 12-myristate 13-acetate (PMA) (50 ng/ml)/ionomycin (2 μg/ml; Sigma-Aldrich, Gillingham, Dorset, UK), respectively. CD107a antibody, monensin (BD GolgiStop, San Jose, CA, USA) and brefeldin A (Sigma, Gillingham, Dorset, UK) were added to cultures at the start of incubation as published previously. 15 Cells were stained with CD56 and CD3 monoclonal antibodies (Fisher Scientific, Pittsburgh, PA, USA), fixed/permeabilized (BD Biosciences), followed by intracellular cytokine staining with interferon-γ (IFN-γ) and TNF-α monoclonal antibodies (Fisher Scientific). NK cytotoxicity was compared at all time points, and with age-matched controls. Cells were acquired on a BD LSRFortessa cytometer (BD Biosciences) (non-viable cells excluded using LIVE/DEAD Aqua Dead-Cell Stain Kit; Life Technologies) and analyzed using the FlowJo software. Surface receptor phenotyping and functional assays were performed in triplicate based on sample availability.
As validation, in a subset of patients (n = 15) with sufficient PBMCs available, we magnetically negatively selected NK cells using the NK Cell Isolation Kit (Miltenyi Biotech, San Diego, CA, USA) and performed 51 chromium release cytotoxicity assays against K562 targets and B-ALL blasts, as published previously. 16 
Coculture experiments
Healthy NK cells were negatively selected and cultured in 96-well plates at 200 000 cells per well for 24 h, in the presence or absence of ALL blasts or B-ALL cell lines (JM-1/RS4;11/MUTZ5) and 20 IU/ml rhIL-2 (PROLEUKIN; Chiron Corporation, Emeryville, CA, USA). Controls included allogeneic negatively selected healthy B cells (Miltenyi Biotec) and NK cells alone. In a subset of experiments, healthy NK cells were cocultured with ALL blasts in transwell devices (96-well/1 μm micropores; Millipore, Millipore Plate, Fisher Scientific) at a 1:1 ratio, and their effector function analyzed. Following coculture, supernatants were evaluated for cytokine production using the ProcartaPlex Human Cytokine Panel immunoassay with the Luminex-100 reader according to the manufacturer's instructions. Supernatants were evaluated for TGF-β1 production using the Human TGF-β1 Platinum ELISA assay (ebiosciences, San Diego, CA, USA).
TGF-β1-blocking experiments ALL blasts and healthy NK cells were cultured in the presence/absence of anti-TGF-β (0.1 μg/μl; TB21) for 24 h. NK cells were then negatively selected and their effector function assessed.
TGF-β1 coculture experiments
Ex vivo selected healthy donor NK cells were cultured in the presence of IL-2 (200 U/ml) for 5 days and TGF-β1 (10 ng/ml) was added to the cells on days 0 and 3 of culture. Surface expression of activating and inhibitory receptors was examined as described above.
P-SMAD-specific phospho-flow cytometry PBMCs from ALL patients at DX (n = 6), IND-29 (n = 6), maintenance therapy (n = 5) and controls (n = 6) were thawed, rested in RPMI/FCS 10% for 4 h and NK cells negatively selected using the NK Cell Isolation Kit. TGF-β1 (Peprotech, Rocky Hill, NJ, USA; Ref100-21) was diluted to 5 ng/μl in HCl and 10 ng/ml added to healthy NK cells for 1 h at 37°C (positive control). Cells were stained with phospho-SMAD2/3 A647 antibody (BD Biosciences) using the PerFix EXPOSE Phospho-Epitopes Exposure Kit (Beckman Coulter, Brea, CA, USA).
Expansion of NK cells
Cryopreserved PBMCs from ALL samples and controls were thaed, resuspended in RPMI 10%/Click's Medium plus 100 IU/ml IL-2 and stimulated with irradiated K562 cells transduced with membrane-bound IL-15/41BB ligand (K562-mb15-41BBL, a gift from Cliona Rooney, Center for Cell and Gene Therapy, Houston, TX, USA) at a ratio of 1:2. T cells were magnetically depleted using CD3 microbeads (Miltenyi Biotec). Following 14 days of culture and expansion, 17 NK cells were harvested for cytotoxicity assays.
Statistical analyses
Values are expressed as means or medians and standard error of the mean. Statistical significance was assessed with Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) using unpaired or paired two-tailed t-test and by nonparametric one-way analysis of variance, as appropriate. P-values r 0.05 were considered significant. To standardize comparisons of median fluorescence intensities (MFIs), we used resolution index (Xpos − Xnegative)/√(SDpos 2 +SDnegative 2 ).
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RESULTS
Patient and control characteristics NK cells from pediatric B-ALL patients were analyzed at DX (n = 50), IND-29 (n = 50) and maintenance therapy. Linked samples lower in ALL patients at DX compared with healthy controls (mean 3.3 ± 0.33% vs 6.2 ± 0.71%, P o 0.0001 and mean 255 ± 48.9 vs 442 ± 48.3/μl, P = 0.016 respectively; Figure 1c) , with comparable frequencies of T cells (data not shown). ALL-NK cells at DX had an abnormal phenotype compared with controls, with increased frequencies of NK cells expressing the inhibitory receptor NKG2A (mean 30.1 ± 2.7% vs 16.6 ± 3.5%, P = 0.007) ( Figure 1d ) and lower frequencies of NK cells expressing the activating receptor NKp46 (mean 23.3 ± 3.2% vs 55.3 ± 7.1%, P o0.0001) (Figure 1e ). We found no significant difference in the expression of NKp30, NKp44, NKG2D (Supplementary Figure 1A) or KIRs in patients compared with controls (data not shown). Interestingly, we found a higher percentage of the immunoregulatory CD56 bright CD16 − CD3 − ALL-NK cells at DX compared with controls, although this did not reach statistical significance (Supplementary Figure 1B) .
NK cell phenotypic abnormalities in ALL patients are associated with impaired effector function We next determined whether these phenotypic abnormalities were associated with altered NK cell functions. Owing to the limited volume of blood available from each patient and the number of assays performed at each time point, we used a flowbased assay and gated on CD56+CD3 − NK cells to assess their ability to degranulate (CD107a positivity) and to produce IFN-γ and TNF-α in response to K562 targets. ALL-NK cells at DX had significantly reduced CD107a degranulation (mean CD56+CD3 − CD107+ 5.8 ± 1.2% vs 13.3 ± 2.4%, P = 0.0027) and IFN-γ production (mean CD56+CD3 − IFN-γ+ 1.5 ± 0.4% vs 4.2 ± 0.7%, P = 0.0005) compared with NK cells from age-matched controls, with comparable release of TNF-α (mean CD56+CD3 − TNF-α+ 2.7 ± 0.9% vs 3.9 ± 0.5%, P = 0.26). Further, ALL-NK cells at DX failed to degranulate or produce effector cytokines in response to Figure 2a) . To validate our flow-based functional data and confirm that cytokine secretion and degranulation correlate with target cell killing, 51 chromium release assay was used as the gold standard to assess the ability of magnetically purified NK cells (495% purity) to kill K562 target cells and autologous B-ALL blasts. This approach also allowed us to exclude the contribution of other effector cells such as T cells to target cell killing, as well as exclude the inhibitory effect of immunosuppressive cells such as regulatory T cells on NK cell function. As shown in Figure 2b , magnetically selected NK cells from ALL patients at diagnosis had significant impairment in their ability to kill K562 targets as well as autologous blasts. ALL cells suppress NK function through the release of soluble factors including TGF-β1 To determine whether ALL blasts induce alterations in allogeneic NK cells, NK cells from five healthy controls were cultured with ALL blasts from 12 patients and three B-ALL cell lines (JM-1, MUTZ5, RS4; 11) at a 1:1 ratio for 24 h. When compared with NK cells cultured alone, coculture of ALL blasts with healthy NK cells induced significant impairment in NK function against K562 targets: namely, CD107a degranulation (mean CD56+CD3 − CD107+ 7.9 ± 1.55%; range 0.5-17% vs 22% ± 2.3; range 18-39%, P = 0.0074), IFN-γ (mean CD56+CD3 − IFN-γ+ 3.6 ± 0.66%; range 0.2-13.8% vs 15.7 ± 0.37%; range 15-18.4%, P o0.0001) and TNF-α secretion (mean CD56+CD3 − TNF-α+ 2.5 ± 0.40%; range 0.35-4.2% vs 14.1 ± 1.53%; range 11.1-16%; P = 0.0015) when compared with NK cells cultured alone (Figures 4a and b) . Although coincubation of NK cells with healthy allogeneic B cells resulted in some inhibition in NK effector function, the degree of suppression was significantly less than that observed with B-ALL blasts (Figure 4b) . In four experiments, sufficient cells were available to test the dose effect of ALL blasts on NK function. At an NK:ALL ratio of 10:1, NK effector abnormalities were still observed but to a lesser extent (Supplementary Figure 3) .
To investigate whether the inhibitory effects of ALL blasts on NK function were mediated by soluble or contact-dependent factors, coculture experiments were performed in transwells to separate ALL blasts and NK cells. The inhibitory effect of ALL blasts on CD107a degranulation and IFN-γ production was seen to a similar extent under both transwell and direct cell-cell contact conditions, suggesting that soluble factors released by ALL blasts induce NK dysfunction (Figure 4c) . We determined the levels of soluble factors known to be increased in other cancers and to alter lymphocyte functions, such as TGF-β1, GM-CSF (granulocyte-macrophage colony-stimulating factor), IL-10, IL-1β, 20 IL-6, 21 IL-18 22 and IL-21 in supernatants collected from the coculture experiments (Supplementary Table 1 ). Under both transwell conditions and cell-cell contact, we found increased levels of several cytokines, most notably TGF-β1 in the supernatants collected from ALL blasts cultured alone or with healthy donor NK cells compared with healthy NK cells cultured alone or with healthy donor B cells. These data confirm ALL blasts to be the source of TGF-β1 in the coculture experiments (Figure 4d ).
Blockade of TGF-β1 partially corrects ALL-induced NK dysfunction As TGF-β1 has been shown to mediate immunomodulatory effects in several cancers, [23] [24] [25] we further explored its contribution to ALL-induced NK dysfunction. The addition of a TGF-β1-blocking antibody to cocultures of NK cells plus ALL blasts partially restored NK function; CD107a suppression reversed by a median of 95% (range 82-110%); IFN-γ by 50% (range 47-74%); and TNF-α by 51% (range 40-72%; (Figure 4e ). Figure 4f summarizes degranulation/cytokine production by healthy NK cells in response to K562 targets following coculture with ALL blasts in the presence or absence of TGF-β1 blockade, compared with healthy NK cells cultured alone.
The TGF-β/SMAD signaling pathway mediates ALL-induced NK dysfunction To further examine the mechanisms by which ALL induces NK dysfunction, we assessed the phosphorylation/activation of molecules known to be important for TGF-β signaling in NK cells. We incubated healthy NK cells with primary ALL blasts and observed a strong induction of SMAD2/3 phosphorylation in NK cells. This effect was completely abrogated by the addition of TGF-β-blocking antibody to the cocultures, indicating that ALL cells secrete TGF-β and induce NK dysfunction by activating the TGF-β/SMAD pathway (Figure 5a ). Using phospho-flow, we evaluated the expression of SMAD2/3 in NK cells from ALL patients at DX, IND-29 and during maintenance therapy (n = 6). Strikingly, the TGF-β/SMAD pathway was constitutively activated in ALL-NK cells at diagnosis (median expression 92.2%; range 65.9-93.1%) compared with that (4.72%; range 1.04-9.15%) in healthy donors (P o 0.0001). SMAD2/3 phosphorylation remained considerably elevated in ALL-NK cells at IND-29 but significantly decreased by maintenance therapy (Figures 5b and c) . NK cell phenotype and function is partially restored in patients at remission To investigate the duration of ALL-induced NK cell abnormalities, we examined the NK phenotype of ALL patients at two remission time points, IND-29 and maintenance therapy. To minimize variability, all maintenance samples were collected during cycles 2-4. At IND-29, we observed partial restoration of phenotype, with an increase in the frequencies of NKp46-expressing NK cells from 24.7 ± 2.9% at DX to 38.6 ± 4.1% (P = 0.009). By maintenance therapy, NKp46 expression had normalized (mean 53.1% vs 24.7% at DX and 38.6% at IND-29; P-values o 0.0001 and 0.001, respectively), and was comparable to that of age-matched controls (mean 53.1 ± 5.4% vs 55.3% ± 6, P = 0.79). However, the frequencies of NKG2A+CD56+CD3 − NK cells remained elevated, even during maintenance therapy (mean 49.2% at maintenance vs 30.1% at DX and 26.8% at IND-29, P = 0.0013 and 0.0001, respectively; Figure 6a) .
Concordant with the phenotypic changes, NK effector function in response to K562 targets was restored in the majority of patients by maintenance therapy (Figure 6b) , associated with normalization of phospho-SMAD2/3 expression (Figures 5b and c) . We found no significant differences in degranulation/cytokine release of maintenance ALL-NK cells against K562 targets compared with healthy control NK cells (mean CD56+CD3 − CD107a+ frequencies 10.3 ± 2.19% vs 13.3 ± 2.38%, P = 0.49; mean CD56+CD3 − IFN-γ+ 2.88 ± 0.50% vs 4.23 ± 0.67%, P = 0.16; mean CD56+CD3 − TNF-α+ 3.91 ± 0.710% vs 3.43 ± 0.554%, P = 0.59; Figure 6b ). The normalization of NK effector responses to K562 targets in the majority of patients corresponded with the morphologic remission and MRD − status observed in 46/50 and 39/50 of patients, respectively.
Ex vivo-expanded and -activated NK cells from ALL patients in remission fail to kill autologous blasts We next assessed whether NK cells from ALL patients in remission could kill autologous blasts cryopreserved at diagnosis. ALL-NK cells collected at IND-29 or maintenance therapy failed to kill/produce effector cytokines in response to autologous blasts in vitro, although ALL-NK cells from the maintenance time point were able to respond to K562 targets (Figures 7a and b) . We therefore explored whether ex vivo expansion/activation of ALL-NK cells collected at IND-29 or maintenance therapy could enhance their cytotoxicity against autologous blasts. NK cells were expanded from PBMCs at IND-29 (median fold expansion 130, range 55-220-fold, n = 4) and maintenance therapy (median fold expansion 183, range 73-389-fold, n = 8). When compared 
DISCUSSION
Understanding the role of the immune system in the control of cancer and the mechanisms mediating immune evasion remains one of the most challenging questions in tumor immunology. If immunotherapy for childhood ALL is to prove successful, a better understanding of the impact of leukemia on the immune system is critical. Here we report an important role for the TGF-β/SMAD signaling pathway in ALL-induced NK immune evasion. We showed that pediatric B-ALL cells alter NK cell function through modulation of their surface receptors, a mechanism observed in other malignancies. 13, [26] [27] [28] By inducing downregulation of activating receptors and upregulation of inhibitory receptors on NK cells, leukemia cells can escape NK recognition. Phenotypic and functional abnormalities were partially reversed following remission induction, with restoration of NKp46 expression but persistently increased inhibitory NKG2A. A possible explanation for the persistent inhibitory phenotype and decreased cytolytic activity at IND-29 is the use of corticosteroids as a standard component of Induction. By maintenance therapy, however, the majority of phenotypic and functional changes had normalized.
Whereas at diagnosis, NK cells showed impaired cytotoxicity against both K562 targets and ALL blasts, with chemotherapy and achievement of remission, there was a progressive improvement in NK cell function against K562 targets. However, at all time points tested, NK cells were unable to recognize autologous blasts. The use of selected NK cells and purified ALL blasts in our experiments eliminated the contribution of other effector cells such as T cells on target cell killing, as well as the inhibitory effect of immunosuppressive cells such as regulatory T cells on NK cell function. Although ex vivo expansion and activation of NK cells from ALL patients collected at remission significantly enhanced their cytotoxicity against K562 targets, there was minimal cytotoxicity against autologous blasts, further supporting the notion that during the course of the disease, ALL cells undergo successful immune editing, resulting in the selection of blasts with resistance to killing by autologous NK cells. As suggested by the partially retained activity of ALL-NK cells to PMA/ionomycin, NK dysfunction in ALL is likely related to impaired NK receptorligand interaction. 29 One mechanism of immune editing may be mediated through MICA/B shedding. 30, 31 Our observation that MICA/B is downregulated on ALL blasts suggests that through shedding of activating ligands, ALL cells may escape NK cell recognition. Intriguingly, in two of three patients with BCR-ABL+ ALL, we observed higher expression levels of MICA/B. In contrast to studies in adult ALL, 32 however, we found no significant differences in the sensitivity of ALL blasts to NK cell killing among patients with different clinical or cytogenetic characteristics, although our study was not powered to address specifically the impact of prognostic factors on susceptibility to NK killing.
The alterations in ALL-NK cells and their reversibility in patients in remission suggest that ALL cells can actively modulate NK cell phenotype and function. Indeed, coculture of ALL blasts with healthy NK cells induced an inhibitory phenotype, as well as significant impairment in NK degranulation and cytokine production against K562 targets. This effect was still present under transwell conditions, suggesting that soluble factors are important in mediating ALL-induced NK dysfunction. Interestingly, coculture of allogeneic B cells with NK cells induced some impairment in NK effector function, albeit to a much lesser extent, likely mediated by regulatory B cells, a subset of B cells with immune suppressive function. [33] [34] [35] We performed a comprehensive analysis of cytokines and growth factors reported to exert suppressive effects on immune effectors [23] [24] [25] and showed significantly higher levels of ALL-derived TGF-β1 in the supernatant of ALL blasts cultured alone or with NK cells compared with NK cells alone. Although we did not have the opportunity to measure directly TGF-β in the sera of our patients, a number of studies have reported elevated serum levels of TGF-β in patients with other lymphoid malignancies such as hairy cell leukemia and multiple myeloma. 36, 37 TGF-β-blocking monoclonal antibodies reversed ALL-mediated NK cell dysfunction, whereas addition of exogenous TGF-β1 to healthy donor NK cells in vitro induced an inhibitory phenotype comparable to that of ALL-NK cells, further supporting a direct role for TGF-β in modulation of NK cell phenotype and function. As a powerful physiological immune suppressant, TGF-β1 suppresses NK effector function through activation of the SMAD signaling pathway. 14, [38] [39] [40] To further investigate TGF-β1-induced NK dysfunction in pediatric ALL, we measured the phosphorylation of SMAD2/3 in healthy NK cells following coculture with primary ALL blasts and showed that ALL blasts use the TGF-β1/SMAD pathway to inhibit NK cytotoxicity. Moreover, we found that ALL-NK cells had significantly elevated phospho-SMAD2/3 expression at DX and IND-29, correlating with impaired effector function. Increased phospho-SMAD2/3 in ALL-NK cells at IND-29 may be related to corticosteroid use during induction, considering the steroid receptor coactivator-1 has been shown to potentiate TGF-β1/ SMAD signaling. 41 Phospho-SMAD2/3 expression had significantly decreased by maintenance therapy, correlating with restoration of NK effector function against K562 targets. Taken together, our study suggests that ALL actively evades innate immune surveillance by inducing changes in NK cells that limit their ability to kill autologous blasts. Numerous avenues are under investigation to enhance NK function, including engager molecules, 42 genetic modification, 43 immunomodulatory blockade and epigenetic therapies. 43 Indeed, a number of drugs commonly used in salvage therapy for relapsed ALL such as bortezomib or valproate have been shown to sensitize ALL cells to NK-mediated lysis in vitro. 44 Studies of NK cell adoptive therapy have shown promise in a number of settings. 43, 44 However, our data do not support the use of autologous NK cells for the immunotherapy of ALL; instead, they support the use of allogeneic NK cells and the development of novel strategies to modulate the TGF-β pathway, such as engineered resistance to TGF-β with the dominantnegative TGF-β type II receptor 40 to protect NK cells from ALLinduced dysfunction.
